The Domino Effect Triggered by the Tethered Ligand of the Protease Activated Receptors

Overview

Journal Thromb Res

Date 2020 Aug 28

PMID 32853981

Citations 14

Authors

Xu Han

Marvin T Nieman

Affiliations

Soon will be listed here.

Abstract

Protease activated receptors (PARs) are G-protein coupled receptors (GPCRs) that have a unique activation mechanism. Unlike other GPCRs that can be activated by free ligands, under physiological conditions, PARs are activated by the tethered ligand, which is a part of their N-terminus that is unmasked by proteolysis. It has been 30 years since the first member of the family, PAR1, was identified. In this review, we will discuss this unique tethered ligand mediate receptor activation of PARs in detail: how they interact with the proteases, the complex structural rearrangement of the receptors upon activation, and the termination of the signaling. We also summarize the structural studies of the PARs and how single nucleotide polymorphisms impact the receptor reactivity. Finally, we review the current strategies for inhibiting PAR function with therapeutic targets for anti-thrombosis. The focus of this review is PAR1 and PAR4 as they are the thrombin signal mediators on human platelets and therapeutics targets. We also include the structural studies of PAR2 as it informs the mechanism of action for PARs in general.

Citing Articles

Endothelial protease-activated receptor 4: impotent or important?.

Rajala R, Griffin C Front Cardiovasc Med. 2025; 12:1541879.

PMID: 39935714 PMC: 11810968. DOI: 10.3389/fcvm.2025.1541879.

Spint1 disruption in mouse pancreas leads to glucose intolerance and impaired insulin production involving HEPSIN/MAFA.

Lin H, Yu I, Cheng M, Chang T, Lin H, Chang Y Nat Commun. 2024; 15(1):10537.

PMID: 39627229 PMC: 11615295. DOI: 10.1038/s41467-024-54927-2.

Hidden Power: PAR4's Role in Liver Damage From Acetaminophen Overdose in Mice.

Kendrick N, Nieman M Arterioscler Thromb Vasc Biol. 2024; 45(1):72-73.

PMID: 39540282 PMC: 11668613. DOI: 10.1161/ATVBAHA.124.321881.

Rivaroxaban as a Protector of Oxidative Stress-Induced Vascular Endothelial Glycocalyx Damage via the IQGAP1/PAR1-2/PI3K/Akt Pathway.

Kitasato L, Yamaoka-Tojo M, Iwaya T, Murayama Y, Ikeda Y, Hashikata T J Vasc Res. 2024; 62(1):22-36.

PMID: 39496251 PMC: 11797952. DOI: 10.1159/000542419.

Glycoprotein V exerts local control of fibrin.

Knauss E, Nieman M Nat Cardiovasc Res. 2024; 2(4):335-336.

PMID: 39195957 DOI: 10.1038/s44161-023-00261-7.

References

Dores M, Chen B, Lin H, Soh U, Paing M, Montagne W . ALIX binds a YPX(3)L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting. J Cell Biol. 2012; 197(3):407-19. PMC: 3341166. DOI: 10.1083/jcb.201110031. View

Ferguson S, Barak L, Zhang J, Caron M . G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol. 1996; 74(10):1095-110. DOI: 10.1139/cjpp-74-10-1095. View

Gurbel P, Bliden K, Turner S, Tantry U, Gesheff M, Barr T . Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2015; 36(1):189-97. PMC: 4836853. DOI: 10.1161/ATVBAHA.115.306777. View

Dowal L, Sim D, Dilks J, Blair P, Beaudry S, Denker B . Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci U S A. 2011; 108(7):2951-6. PMC: 3041116. DOI: 10.1073/pnas.1014863108. View

Covic L, Misra M, Badar J, Singh C, Kuliopulos A . Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002; 8(10):1161-5. DOI: 10.1038/nm760. View

Compton S, Cairns J, Palmer K, Hollenberg M, Walls A . A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J Biol Chem. 2000; 275(50):39207-12. DOI: 10.1074/jbc.M007215200. View

Ghanouni P, Gryczynski Z, Steenhuis J, Lee T, Farrens D, Lakowicz J . Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001; 276(27):24433-6. DOI: 10.1074/jbc.C100162200. View

Ayala Y, Cantwell A, Rose T, Bush L, Arosio D, Di Cera E . Molecular mapping of thrombin-receptor interactions. Proteins. 2001; 45(2):107-16. DOI: 10.1002/prot.1130. View

Chackalamannil S, Wang Y, Greenlee W, Hu Z, Xia Y, Ahn H . Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51(11):3061-4. DOI: 10.1021/jm800180e. View

10.

Kahn M, Shapiro M, Ishihara H, Coughlin S . Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999; 103(6):879-87. PMC: 408153. DOI: 10.1172/JCI6042. View

11.

Jacques S, LeMasurier M, Sheridan P, Seeley S, Kuliopulos A . Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem. 2000; 275(52):40671-8. DOI: 10.1074/jbc.M004544200. View

12.

Andrade-Gordon P, Maryanoff B, Derian C, Zhang H, Addo M, Darrow A . Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999; 96(22):12257-62. PMC: 22903. DOI: 10.1073/pnas.96.22.12257. View

13.

Edelstein L, Simon L, Lindsay C, Kong X, Teruel-Montoya R, Tourdot B . Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014; 124(23):3450-8. PMC: 4246040. DOI: 10.1182/blood-2014-04-572479. View

14.

Faruqi T, Weiss E, Shapiro M, Huang W, Coughlin S . Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem. 2000; 275(26):19728-34. DOI: 10.1074/jbc.M909960199. View

15.

Mosnier L, Sinha R, Burnier L, Bouwens E, Griffin J . Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012; 120(26):5237-46. PMC: 3537315. DOI: 10.1182/blood-2012-08-452169. View

16.

Kennedy A, Ballante F, Johansson J, Milligan G, Sundstrom L, Nordqvist A . Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacol Transl Sci. 2020; 1(2):119-133. PMC: 7088944. DOI: 10.1021/acsptsci.8b00019. View

17.

Liu L, Vu T, Esmon C, Coughlin S . The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 1991; 266(26):16977-80. View

18.

Ma J, Burstein E . The protease activated receptor 2 (PAR2) polymorphic variant F240S constitutively activates PAR2 receptors and potentiates responses to small-molecule PAR2 agonists. J Pharmacol Exp Ther. 2013; 347(3):697-704. DOI: 10.1124/jpet.113.208744. View

19.

Malito E, Faleri A, Lo Surdo P, Veggi D, Maruggi G, Grassi E . Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A. 2013; 110(9):3304-9. PMC: 3587270. DOI: 10.1073/pnas.1222845110. View

20.

French S, Arthur J, Tran H, Hamilton J . Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Rev. 2014; 29(3):179-89. DOI: 10.1016/j.blre.2014.10.006. View